The ‘Toolkit’ is targeted at practitioners responsible for implementing recovery programmes, their objective to provide a ‘how to’ guide on development, implementing and managing complex post-disaster recovery programmes.
Disaster Recovery Toolkit
Disaster Recovery Toolkit
December 2015
National guidelines for of Clubfoot
(New 2015)
Scoping question: Within the context of mental health and developmental assessment of children and youth, what are the effective strategies for detecting maltreatment?
Early childhood matters.
This document looks at specific issues regarding the development of young children, in particular from a psychosocial perspective. It is published twice per year by the Bernard van Leer Foundation. The views expressed in Early Childhood Matters are those of the authors and... do not necessarily reflect those of the Bernard van Leer Foundation.
more
Gender-based violence is a life-threatening, global health and human rights issue that violates international human rights law and principles of gender equality. It is also a threat to lasting peace and an affront to our common humanity. United Nations Member States have called for urgent action to ...end GBV in emergencies, recognizing that in crises, the risk of GBV is heightened, particularly for women and adolescent girls.
more
This is one of seven Medical Peace Work cases.
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more